Humacyte responds to media coverage with SEC filing

Investing.com

Published Mar 27, 2025 05:36PM ET

Humacyte responds to media coverage with SEC filing

DURHAM, NC – Humacyte, Inc. (NASDAQ:HUMA), a biotechnology company specializing in biological products, has made a regulatory filing today in response to a recent article. The company, with a market capitalization of $262 million and currently trading at $2.01, has seen its shares decline 37% in the past week. According to InvestingPro analysis, the stock appears undervalued at current levels. The company, headquartered in Durham, North Carolina, provided a statement through Exhibit 99.1, as part of its Form 8-K submission to the U.S. Securities and Exchange Commission (SEC).

The statement issued by Humacyte addresses specific points raised in a New York Times (NYSE:NYT) article dated March 27, 2025. While the contents of the statement were not disclosed in the SEC filing, the company has clarified that the information should not be interpreted as "filed" under Section 18 of the Exchange Act, nor should it be incorporated by reference in any future filings unless explicitly stated.

Humacyte, previously known as Alpha Healthcare Acquisition Corp. before a name change on July 16, 2020, is recognized under the Standard Industrial Classification code 2836, which pertains to biological products excluding diagnostic substances. The company's common stock and redeemable warrants are both listed on The Nasdaq Stock Market under the symbols HUMA and HUMAW, respectively. InvestingPro data reveals the company faces financial challenges, with an EBITDA of -$105 million in the last twelve months and a weak overall financial health score.

The company has identified itself as an emerging growth company and is subject to the reporting requirements set forth by federal securities laws. The SEC filing made today by Humacyte's Chief Financial Officer, Chief Corporate Development Officer, and Treasurer, Dale A. Sander, ensures that the company maintains transparency with its investors and complies with the necessary regulations.

Investors and interested parties can refer to the Form 8-K for a complete view of the disclosures made by Humacyte. The filing is based on a press release statement and is intended to provide shareholders with the most current information regarding the company's position on the matters discussed in the media. Analyst consensus remains optimistic despite recent challenges, with price targets ranging from $5 to $25 per share. For comprehensive analysis and additional insights, investors can access the detailed Pro Research Report available on InvestingPro , which covers this and 1,400+ other US stocks.

In other recent news, Humacyte, Inc. has announced an underwritten public offering of 25 million shares at $2 each, aiming to raise $50 million in gross proceeds. The funds are intended for the commercialization of its SYMVESS™ product for vascular trauma, further development of its product pipeline, and general corporate purposes. The offering, managed by TD Cowen, Barclays, and BTIG, includes an option for underwriters to purchase an additional 3.75 million shares, and is expected to close around March 27, 2025. This move follows a shelf registration statement filed with the SEC in September 2022.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Separately, Humacyte has published a Budget Impact Model in the Journal of Medical Economics, suggesting that its SYMVESS product could lead to cost savings for trauma centers and third-party payers by reducing amputation and infection rates. The study estimates per-patient costs using SYMVESS at Level I trauma centers to be $121,615, compared to higher costs for other graft types. Additionally, Benchmark analyst Bruce D. Jackson reaffirmed a Buy rating for Humacyte with a $17 price target, highlighting a study that suggests SYMVESS could offer similar outcomes to autologous vein grafts in treating extremity arterial injuries.

Humacyte's recent efforts also include a research partnership with Trestle Bio to explore creating vascularized organs for transplantation. The company's early launch activities are reportedly progressing well, with an increasing number of hospitals starting the Value Analysis Committee process. The publication of the budget impact model is expected to support the company's sales efforts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes